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Abstract
The plasma membrane calcium–calmodulin-dependent ATPase (PMCA) is a calcium-extruding enzy-
matic pump that ejects calcium from the cytoplasm to the extracellular compartment. Although in
excitable cells such as skeletal and cardiac muscle cells PMCA has been shown to play only a minor
role in regulating global intracellular calcium concentration, increasing evidence points to an important
role for PMCA in signal transduction, in particular in the nitric oxide signaling pathway. Moreover, recent
evidence has shown the functional importance of PMCA in mediating cardiac contractility and vascular
tone. Here we describe a method in determining PMCA activity in the microsomal membrane prepara-
tion from cultured cells that overexpress specific isoform of PMCA by using modified coupled enzyme
assay.
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1. Introduction
The plasma membrane calcium–calmodulin-dependent ATPase
(PMCA) is a ubiquitous calcium transporter that pumps cal-
cium from the cytoplasm to the extracellular matrix. In most cell
types, the role of PMCA is crucial in maintaining low intracel-
lular calcium concentration. Four different PMCA genes (named
PMCA1–4) and more than 20 splice variants have been described.
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The structure of PMCA, isoform diversity, splice variants, and tis-
sue distribution have previously been reviewed in great detail (1).
Unlike in non-excitable cells, where PMCA plays a major role
in calcium extrusion, in excitable cells such as cardiac and skeletal
muscle PMCA has only a minor role in the regulation of cytoso-
lic calcium. In these cells, calcium is mainly removed through the
sarcoplasmic reticulum calcium ATPase (SERCA) and the sodium
calcium exchanger (NCX) (2). However, increasing evidence
suggests that PMCA plays a more important role in signal trans-
duction. Two main characteristics of a signaling molecule dis-
played by PMCA are the ability to interact with signaling pro-
teins (3) and its localization in caveolae (4). Recent evidence
from our laboratory suggested that PMCA has a role in medi-
ating nNOS activity (5, 6) and demonstrated the physiological
relevance of this novel signaling complex in regulating cardiac
contractility (7, 8).
As PMCA plays an essential role in cell function develop-
ment of an assay to measure its activity is very important. The
use of human erythrocyte ghosts was common in the preparation
of purified PMCA for this purpose (9). However, this will yield
mainly PMCA4 as this is the main isoform expressed in human red
blood cells. Moreover, a large amount of human blood is needed
to obtain a substantial amount of good-quality purified PMCA.
In this chapter we describe a method for measuring PMCA activ-
ity in the microsomal membrane preparation from cultured cells
that overexpress PMCA. Measurement of PMCA activity is based
on a coupled enzyme ATPase activity. The coupled enzyme assay
is based on regeneration of PMCA-dependent release of ADP by
pyruvate kinase, which converts phosphoenolpyruvate to pyru-
vate. Then, pyruvate is converted to lactate by lactate dehydroge-
nase using NADH (see Fig. 18.1). Detection of NADH decline
Fig. 18.1. Schematic diagram of PMCA activity assay. The phosphorylation of the aspar-
tate residue in the catalytic domain of PMCA by ATP results in the generation of ADP + Pi.
Then, the ADP is used by pyruvate kinase to generate pyruvate from phosphoenolpyru-
vate. Pyruvate produced by this reaction will be converted to lactate by lactate dehydro-
genase. This reaction is coupled to the oxidation of NADH to NAD. The degradation of
NADH can be monitored at 340 nm wavelength.
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rate at 340 nm will determine the activity of the pump. An
adaptation of this method in 96-well format is also discussed,
which could be useful for the development of a high-throughput
assay system.
2. Materials
2.1. Cell Culture and
Infection with
Adenovirus
1. Dulbecco’s modified Eagle’s medium (DMEM).
2. Fetal bovine serum (FBS).
3. Penicillin/streptomycin.
4. Non-essential amino acids.
5. Human embryonic kidney cells (HEK293) (ATCC).
6. Trypsin–EDTA (1X) liquid (0.05% trypsin, 0.53 mM
EDTA tetra sodium salt).
7. AdEasy Adenoviral Vector System.
8. BJ5183 electroporation competent Escherichia coli cells.
9. LB broth medium.
10. LipofectamineTM 2000.
11. PMCA4 recombinant adenovirus (see Section 3 for the
cloning and generation of adenovirus) (see Note 1).
2.2. Microsomal
Membrane
Preparation
1. Harvest solution: 1X PBS, 0.26% 2 mg/ml aprotinin, 0.11%
2 mg/ml leupeptin, and 0.1% 0.1 M phenylmethylsulfonyl
fluoride (PMSF).
2. Hypotonic solution: 10 mM Tris–HCl, pH7.5, 1 mM
MgCl2, 0.5 mM EGTA, 2 mM DTT, 0.2% 2 mg/ml apro-
tinin, and 0.05% 2 mg/ml leupeptin.
3. Homogenate solution: 10 mM Tris–HCl, pH 7.5, 2 mM
DTT, 0.38 M sucrose, 0.3 M KCl, 0.2% 2 mg/ml aprotinin,
and 0.05% 2 mg/ml leupeptin.
4. Final solution: 10 mM Tris–HCl, pH 7.5, 1 mM
DTT, 0.19 M sucrose, 0.15 M KCl, 0.2% 2 mg/ml
aprotinin, 0.05% 2 mg/ml leupeptin, and 0.02 mM
CaCl2.
2.3. Coupled Enzyme
Assay
1. Coupled enzyme assay reaction mixture: 50 mM HEPES–
Tris, pH 7.4, 160 mM KCl, 2 mM MgCl2, 5 mM NaN3,
1 μg/ml alamethicin, 1 mM ATP–Tris, 1 mM phos-
phoenolpyruvate, 1 U/ml pyruvate kinase, 0.6 mmol/L
NADH, 1 U/ml lactate dehydrogenase.
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2. Calcium and calmodulin mixture: 5 μg of calmodulin and 4
μM-free calcium (see Note 2).
3. Spectrophotometer able to read at 340 nm wavelength.
4. Microplate reader with 340 nm wavelength filter.
3. Methods
3.1. Cell Culture for
HEK293 Cells
Maintained human embryonic kidney (HEK293) cells in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented with
10% fetal bovine serum (FBS), 1% penicillin/streptomycin, and
1% non-essential amino acids. Cells are passed when they reach
75–90% confluence. To passage the cells, remove the medium
from the tissue culture flask and wash the cells twice with
phosphate-buffered saline (PBS). Then, add 5 ml of trypsin–
EDTA (1X) liquid to each flask and incubate for 5 min at 37◦C.
To neutralize trypsin, add 10 ml of the culture medium to each
flask. Cells from one flask are split either into two or three flasks
and topped up to 25 ml medium in each flask.
3.2. Generation of
Recombinant
Adenovirus for PMCA
Overexpression
1. AdEasy Adenoviral Vector System is used to clone the
PMCA4b cDNA to the adenoviral vector. The PMCA4b
cDNA is cloned to the shuttle vector pShuttle-CMV to
obtain pShuttle-CMV-PMCA4b. As a control, an aden-
ovirus overexpressing LacZ is used. To generate recom-
binant adenoviral vectors carrying CMV-PMCA4b or
CMV-LacZ constructs, linearize pShuttle-hPMCA4b and
pShuttle-CMV-LacZ using PmeI restriction enzyme. Pre-
cipitate linearized vectors (using three volumes of absolute
ethanol), then dephosphorylate, and gel purify.
2. Mix 1 μg of linearized/dephosphorylated shuttle vector and
100 ng of pAdEasy-1 with 40 μl BJ5183 electro-competent
E. coli on ice.
3. Electroporate cells with a single pulse using Gene-pulser set
at 200 , 2.5 kV, and 25 μF.
4. Add 1 ml of LB broth medium to each transformation and
incubate at 37◦C for 1 h.
5. Plate cells onto LB agar plates containing 50 μg/ml
kanamycin and incubate overnight at 37◦C.
6. Select small colonies from the plates (large colonies usu-
ally represent re-linearization of the shuttle vector). Grow
selected colonies in small scale cultures (~5 ml of LB broth
with kanamycin).
7. Check plasmids for homologous recombination by digestion
with PacI on a 0.75% agarose gel.
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3.3. Generation of
Recombinant
Adenovirus Particles
1. Plate HEK293 cells at a density of 0.7 × 106 cells per
25 cm2 flask 24 h prior to transfection.
2. Transfect 5 μg of linearized adenoviral plasmids into
HEK293 cells using 10 μl LipofectamineTM 2000.
3. Replace the medium 24 h after transfection and then every
48 h. Cells producing adenovirus will appear as patches
of rounding dying cells. These cells will lyse and release
adenoviral particles which subsequently infect neighboring
cells, then plaques start to form. When the majority of
cells are detached, a primary stock of adenovirus can be
prepared.
4. Collect floating and attached cells in the growth medium
by pipetting it up and down.
5. Pellet cells by centrifugation (1,000×g for 5 min).
6. Resuspend each flask of cells in 0.5 ml PBS and then per-
form four rounds of rapid freezing and thawing by trans-
ferring between a dry ice/methanol bath and a 37◦C water
bath (for 5 min each).
7. Remove cell debris by centrifugation at 13,000×g for
10 min. The supernatant contains the recombinant ade-
novirus.
8. Use 10 μl of the primary stock to infect a 175 cm2 flask
of 70% confluent HEK293 cells, change culture medium
every 2–3 days until plaques formed.
9. Once the majority of cells have detached, harvest the cells
and isolate adenovirus by freeze–thawing. Use the sec-
ondary stock to infect 20 flasks of HEK293 cells and repeat
the procedure above to provide a tertiary stock.
10. Use freezing and thawing method to purify the adenovirus
particles from the tertiary stock (see Note 3).
11. In order to determine the number of adenovirus particles
in the tertiary preparations, plate HEK293 cells at 5 × 103
cells/well (in 96-well plate) in a total volume of 100 μl
medium. After 24 h remove the medium and replace with
100 μl of serially diluted adenovirus stocks (1 × 10–2 to
7.63 × 10–12).
12. Analyze each dilution in triplicate. After 24 h, add 100 μl
of fresh DMEM (with 10% FBS) to each well. Change
the medium on day 4 and monitor plaque formation
each day.
13. Eight days after infection, use the final dilution which
shows plaque formation as the endpoint of the assay. From
knowing the number of adenovirus particles the infection
process can be standardized (see Table 18.1).
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Table 18.1
Determination of adenovirus PFU from serial dilutions
Dilution PFU/mL Dilution PFU/mL
10–2 1×103 7.81×10–9 1.28×109
10–3 1×104 3.91×10–9 2.56×109
10–4 1×105 1.95×10–9 5.12×109
10–5 1×106 9.77×10–10 1.02×1010
10–6 1×107 4.88×10–10 2.05×1010
5×10–7 2×107 2.44×10–10 4.1×1010
2.5×10–7 4×107 1.22×10–10 8.19×1010
1.25×10–7 8×107 6.1×10–11 1.64×1011
6.25×10–8 1.6×108 3.05×10–11 3.28×1011
3.12×10–8 3.2×108 1.53×10–11 6.55×1011
1.56×10–8 6.4×108 7.63×10–12 1.31×1012
3.4. Microsomal
Membrane
Preparation
1. Plate HEK293 cells in 100 mm tissue culture plates, at a
density of 4.5 × 106 cells/plate, 24 h prior to virus infec-
tion.
2. Infect cells in 10 ml of DMEM plus 10% FBS by 25 MOI
(see Note 1) of the indicated recombinant adenovirus,
PMCA4b or LacZ (control) virus, for 48 h.
3. After 48 h, remove the medium and wash cells three times
with PBS.
4. After washing, harvest cells in 5 ml of harvest medium and
then centrifuge cells at 3000×g for 10 min at 4◦C.
5. Incubate the cell pellet in 3 ml hypotonic solution for
10 min in ice.
6. Then homogenize cells using Dounce homogenizer for 40
strokes before the addition of 3 ml homogenate solution.
7. Homogenize cells slowly for another 20 strokes to seal the
vesicles.
8. Spin cell homogenate at 3500× g for 20 min to remove
cell debris.
9. Then, add 60 μl 0.25 mM EDTA and 1.08 ml of 2.5 M
KCl to the supernatant.
10. Centrifuge supernatant at 100,000×g for 40 min at 4◦C
to pellet the microsomes. Finally resuspend the pellet in
0.4 ml final solution and measure protein concentration
using standard bicinchoninic acid (BCA) protein assay kit
(see Note 4).
Measurement of PMCA Activity 339
3.5. Coupled Enzyme
Assay Measuring
Ca+2-Dependent
ATPase Activity
1. All measurements are carried out at 37◦C using Ultrospec
3000 Spectrophotometer setup at 340 nm wavelength.
2. Add 500 μl of coupled enzyme assay reaction mixture to a
quartz cuvette and pre-warmed to 37◦C. Then, record the
baseline activity for 20 min after addition of 20 μg microso-
mal preparation to the reaction mixture.
3. To start the ATPase activation, add 4 μM calcium followed
by the addition of 5 μg calmodulin to the reaction. Then,
record the decrease of NADH at 340 nm absorbance over
5 min following each addition.
4. To stop the Ca+2-dependent ATPase activity, add 2 mM
EGTA and follow the reaction for another 5 min.
5. To stop the calcium- and magnesium-dependent activity,
add 1 mM EDTA to the reaction mixture.
6. The Ca+2/calmodulin-dependent ATPase activity can be
calculated by subtracting the fitted slopes. Figure 18.2
described representative trace with control microsomes and
Fig. 18.3 described representative trace with microsomes
from cells overexpressing PMCA4.
Fig. 18.2. Representative trace of ATPase assay using microsomal particles from cells infected with LacZ overexpressing
virus as a negative control. The decrease of absorbance at 340 nm was mainly due to spontaneous degradation of NADH.
No significant changes were observed after the addition of either calcium or calcium–calmodulin.
3.6. Adaptation of the
Assay in 96-Well
Format
We have optimized this assay to be conducted in a 96-well format
(see Fig. 18.4). A microplate reader with 340 nm filter is needed.
For controls, prepare wells containing microsomes only, micro-
somes + calcium, and microsomes + calcium and calmodulin.
Protocol:
1. All the measurements are carried out at 37◦C in an Ascent
microplate reader.
2. Add 250 μl of coupled enzyme assay reaction mixture in
each well (pre-warm to 37◦C). Record the baseline activity
for 30 min after addition of 10 μg microsomal preparation
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Fig. 18.3. Representative trace of ATPase assay using microsomal particles from cells
infected with PMCA4 overexpressing virus. The decrease of absorbance at 340 nm
after addition of calcium–calmodulin represented the calcium–calmodulin-dependent
ATPase, which was mainly due to the PMCA4 activity.
Microsomes + 
Microsomes + 
Calcium/Calmodulin
Microsomes 
no calcium or calmodulin
Fig. 18.4. Representative trace from 96-well format PMCA assay. About 20 μg of microsomes from cells overexpressing
PMCA4b was added to each well. In columns 1–3, PMCA4b was activated with 4 μM free calcium. In columns 4–6, the
pump was activated with 4 μM free calcium, and 5 μg calmodulin. Columns 7–9 served as negative controls.
to 250 μl of the reaction mixture. Monitor the reduction of
NADH by automatic scanning setup at 30 s intervals.
3. To start the ATPase activation, add calcium and calmod-
ulin mixture to the reaction and then follow the 340 nm
absorbance for another 30 min.
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4. Add substance (inhibitor/activator) to be tested and record
the absorbance at 340 nm for another 30 min.
5. To stop the Ca+2-dependent ATPase activity, add 2 mM
EGTA and continue the reaction for another 15 min.
6. Calculate the Ca+2/calmodulin-dependent ATPase activity
using the equation below. Use the fitted slopes in each step
to determine the effects of each substance added.
3.7. Data Analysis Enzyme activity is expressed as the rate of NADH reduction per
milligram microsomal protein. It can be calculated using the fol-
lowing equation:
E =
( −S
6.22 × P
)
× 250
where E = enzyme activity (mM NADH/min/mg protein)
S = fitted slope (per minute) at the last 10 min of each mea-
surement
6.22 is millimolar extinction coefficient of NADH at 340 nm
and 37◦C
P = microsomal protein added (in milligram protein)
250 is the reaction volume in μl
4. Notes
1. The amount of adenovirus added in the experiments
depends on the number of cells plated. For example, addi-
tion of similar number of adenovirus particles to the cells will
give a multiplicity of infection (MOI) of 1. In most exper-
iments, we infected cells with an MOI of 25, meaning the
number of adenovirus particles added was 25 times more
than the number of cells plated. Cells were infected for 48 h
before harvesting.
2. Free calcium concentration in the solution is calculated
using Fabiato equation. A free software to calculate
the free calcium (MaxChelator) can be downloaded
from the following website: http://www.stanford.edu/
~cpatton/downloads.htm.
3. Purified adenovirus tertiary stock needs to be aliquoted in
small volume (30 μl) and stored at –80◦C. We have found
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that repeated freeze and thaw of the virus stock will reduce
the virus viability.
4. The microsomes are resuspended in the final solution at the
concentration of 2 mg/ml and should be stored as 200 μl
aliquots in liquid nitrogen. Storing the microsomes in liquid
nitrogen will preserve the activity better than storing in 80◦C
freezer.
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